Strep skin infection (Impetigo) - Symptoms, Causes, Treatment & Prevention

```html

Overview

Impetigo is a common, highly contagious bacterial skin infection most often caused by Staphylococcus aureus or Streptococcus pyogenes (group A streptococcus). Although the infection can involve either organism, “strep skin infection” typically refers to cases where S. pyogenes is the dominant pathogen.

• Age group most affected: Children 2‑5 years old, but adults can be infected, especially when they have skin breaks or compromised immunity.
• Global prevalence: Impetigo accounts for up to 5 % of all outpatient dermatology visits in the United States and up to 12 % of school‑aged children in low‑ and middle‑income countries (WHO, 2022).
• Seasonality: Warm, humid weather increases transmission because sweat and skin maceration favor bacterial growth.

Symptoms

Impetigo can appear in two classic forms—non‑bullous (most common) and bullous. The sign‑and‑symptom profile may overlap, so an overview of all possible findings is helpful.

• Red sores or papules: Small, itchy, reddish bumps that quickly rupture.
• Honey‑colored crusts: After the lesion ruptures, a thin, yellow‑brown crust forms—the hallmark of non‑bullous impetigo.
• Blisters (bullous impetigo): Larger, fluid‑filled vesicles that later break, leaving a thin, clear or yellowish membrane.
• Itching or mild burning: Lesions are often uncomfortable, prompting scratching, which spreads the infection.
• Location: Face (especially around the nose and mouth), hands, and feet are typical in children; adults more often have lesions on the lower extremities.
• Swelling or redness around the lesion: Mild local inflammation is common.
• Fever and malaise: Generally absent in localized disease but may appear in extensive infection.
• Regional lymphadenopathy: Enlarged, tender lymph nodes near the affected area in severe cases.

Causes and Risk Factors

Impetigo results from bacterial colonization of damaged skin. The two main pathogens are:

1. Streptococcus pyogenes (Group A Strep): Produces exotoxins that destroy epidermal cells, leading to blistering.
2. Staphylococcus aureus: Often methicillin‑sensitive (MSSA) but can be methicillin‑resistant (MRSA) in some communities.

Key risk factors that increase the likelihood of infection include:

• Breaks in the skin (scrapes, insect bites, eczema, atopic dermatitis).
• Close contact environments—daycare centers, schools, sports teams, military barracks.
• Warm, humid climate that softens skin.
• Compromised immune system (e.g., diabetes, HIV, chemotherapy).
• Recent viral skin conditions such as chickenpox or herpes simplex.
• Living in overcrowded housing or having poor hygiene facilities.

Diagnosis

Diagnosis is primarily clinical, based on the appearance of characteristic lesions. However, laboratory confirmation may be required when:

• Lesions are atypical or do not improve with first‑line therapy.
• There is concern for MRSA or other resistant organisms.
• Severe systemic symptoms suggest deeper infection.

Clinical examination

Healthcare providers will assess lesion morphology, distribution, and signs of secondary infection.

Microbiologic testing

1. Culture of lesion exudate: Swab the base after gently removing the crust. Results guide antibiotic selection, especially if MRSA prevalence is high.
2. Rapid antigen detection test (RADT): Similar to streptococcal throat testing, can be used on skin specimens in some labs.
3. Gram stain: Provides quick visual confirmation of Gram‑positive cocci.

Additional investigations (rare)

If cellulitis, lymphangitis, or deeper soft‑tissue infection is suspected, a physician may order a CBC, ESR, or imaging (ultrasound) to rule out abscess formation.

Treatment Options

Effective treatment eliminates bacteria, reduces contagion, and prevents complications. Choice of therapy depends on severity, patient age, and local resistance patterns.

Topical antibiotics

• Mupirocin 2 % ointment: Applied 3 times daily for 5 days; effective against MSSA and Group A Strep. Recommended for limited (<5 lesions) disease.
• Retapamulin 1 % ointment: Alternative for patients with mupirocin intolerance; 2 times daily for 5 days.

Oral antibiotics

Systemic therapy is indicated for extensive disease, bullous impetigo, or failure of topical agents.

First‑line (unless MRSA suspected)	Typical Dose & Duration
Dicloxacillin 500 mg PO q6h	7‑10 days
Cephalexin 500 mg PO q6h	7‑10 days
Clindamycin 300 mg PO q6h	7‑10 days (covers MRSA)

For confirmed MRSA, options include trimethoprim‑sulfamethoxazole, doxycycline (≥8 y), or linezolid.

Adjunctive measures

• Warm compresses: Help soften crusts for easier cleaning.
• Gentle cleansing: Use mild soap and water to remove secretions; pat dry.
• Hand hygiene: Wash hands frequently, especially after touching lesions.

When to consider procedural intervention

Large bullae may be drained under sterile conditions to relieve discomfort, but this should be performed by a healthcare professional to avoid spreading infection.

Living with Strep Skin Infection (Impetigo)

Even after starting treatment, daily habits can speed recovery and limit spread.

• Keep lesions clean and covered: Use breathable, non‑adhesive dressings (e.g., gauze with petroleum jelly).
• Avoid scratching: Trim fingernails short; consider disposable gloves for children.
• Launder contaminated items daily: Bedding, towels, and clothing should be washed in hot water (≥60 °C) and dried on high heat.
• Stay home from school or work: Until 24 hours after starting effective therapy, to reduce transmission.
• Monitor for spreading: New lesions often appear near the original site; document changes and inform your clinician if they increase.
• Hydration and nutrition: Adequate fluid intake and a balanced diet support immune function.

Prevention

Because impetigo spreads by direct contact, simple hygiene practices are highly effective.

1. Hand washing: Soap and water for at least 20 seconds, especially after touching a lesion.
2. Wound care: Clean minor cuts or abrasions promptly; apply an over‑the‑counter antibacterial ointment.
3. Avoid sharing personal items: Towels, razors, clothing, or sports equipment.
4. Cover existing skin conditions: Treat eczema or fungal infections to reduce entry points for bacteria.
5. Environmental measures: Keep communal areas (playgrounds, gyms) clean and dry.
6. Vaccination status: While no vaccine exists for impetigo, staying up‑to‑date on tetanus and influenza can prevent secondary skin infections.

Complications

When left untreated, impetigo can lead to serious outcomes.

• Cellulitis: Deeper skin infection that may require intravenous antibiotics.
• Post‑streptococcal glomerulonephritis (PSGN): Immune‑complex disease affecting kidneys; occurs in ~1‑3 % of children after Group A Strep skin infections (CDC, 2021).
• Rheumatic fever: Rare after skin infection but possible; involves heart, joints, and nervous system.
• Scarring or pigment changes: Especially if lesions are picked or become ulcerated.
• Systemic spread (bacteremia, sepsis): Uncommon but life‑threatening, more likely in immunocompromised patients.

When to Seek Emergency Care

---

Sources: Mayo Clinic, CDC, WHO, National Institutes of Health (NIH), Cleveland Clinic, *Journal of Clinical Microbiology* 2023; *British Journal of Dermatology* 2022.

```